Celtek Peptides Supplies Materials for Laboratory Research
Products designated For Research Use Only by Celtek Peptides are sold solely for legitimate laboratory research and development purposes.
Unless a product page expressly states otherwise, these materials are not intended for:
- Human use
- Veterinary use
- Injection or administration
- Diagnosis
- Treatment or prevention of disease
- Therapeutic use
- Cosmetic use
- Food use
- Dietary supplementation
Celtek Peptides supplies research chemicals and peptides to qualified researchers and organizations for appropriate in-vitro and laboratory research.
Research-use-only materials should be handled by individuals with the knowledge, facilities, and procedures appropriate for the compounds being studied.
What Does “For Research Use Only” Mean?
“For Research Use Only,” often shortened to RUO, describes the intended purpose of a research material.
For Celtek products carrying this designation, the material is supplied as a laboratory research chemical rather than as a drug or other product intended to be administered to a person or animal.
Examples of appropriate research applications may include:
- Analytical chemistry
- Method development
- Receptor research
- Cell-culture experiments
- In-vitro biochemical assays
- Peptide stability studies
- Structural and molecular research
- Laboratory reference work
- Pharmaceutical research and development conducted within an appropriate research setting
The exact research application depends on the particular compound.
Research Chemicals Are Not Medicines
A research peptide should not be confused with an FDA-approved medication.
FDA-approved drug products undergo a regulatory process that evaluates areas including:
- Manufacturing controls
- Identity and strength
- Purity
- Stability
- Safety
- Effectiveness
- Labeling
- Intended route of administration
- Approved indications
An RUO peptide supplied as a laboratory material has not necessarily gone through those processes.
Analytical testing of a research peptide does not change this distinction.
For example, a peptide may have:
99%+ HPLC purity
and
an observed molecular mass consistent with the expected compound
while still not being approved, sterile, or suitable for administration to humans or animals.
Analytical Purity Does Not Establish Human Safety
Celtek uses analytical methods such as HPLC and mass spectrometry to characterize research materials.
Those methods are useful for answering specific scientific questions.
HPLC can provide information about chromatographic purity.
Mass spectrometry can provide evidence supporting molecular identity.
However, these tests do not by themselves establish:
- Human safety
- Veterinary safety
- Sterility
- Endotoxin status
- Clinical effectiveness
- An approved dosage
- An approved route of administration
- Pharmaceutical manufacturing status
Researchers should interpret a Certificate of Analysis according to the tests actually reported rather than assuming that a high purity result establishes properties that were never tested.
Learn more on our Peptide Quality Standards and Testing & Certificates of Analysis pages.
“Research Use Only” Is About Intended Use, Not Just a Label
This distinction is especially important.
Placing the words:
FOR RESEARCH USE ONLY
NOT FOR HUMAN CONSUMPTION
on a vial or website does not automatically determine how a product is viewed under federal law.
FDA has repeatedly taken the position that it considers the overall evidence of intended use, including statements made on websites, product pages, social media, labeling, and other promotional material.
In a March 2026 warning letter to a peptide seller, FDA specifically noted that products labeled “Research Use Only” and “not intended for human consumption” were nevertheless considered drugs intended for human use because other website content indicated an intended effect on the human body.
FDA made the same point in a June 2026 warning letter involving another peptide business.
For this reason, Celtek’s research-use policy applies not only to the label but to the purpose for which the products are offered.
Celtek Does Not Provide Medical Dosing Instructions
Celtek Peptides does not provide individualized medical advice or instructions for administering research-use-only products.
Information contained in the Celtek research library may discuss:
- Doses used in published clinical trials
- Experimental concentrations used in laboratory studies
- Pharmacokinetics
- Receptor activity
- Drug development
- Published adverse events
- Analytical calculations
Those discussions are provided to explain the scientific literature.
They should not be interpreted as:
- Personal dosing recommendations
- Prescribing information
- Instructions for self-administration
- Treatment recommendations
- Medical advice
A description of what researchers used in a clinical trial is not the same thing as recommending that dose outside the study.
Educational Content Does Not Change Product Status
Celtek publishes educational material covering peptide chemistry and emerging research.
This includes articles about subjects such as:
- Peptide structure
- Analytical purity
- HPLC
- Mass spectrometry
- Lyophilization
- Stability
- Clinical trials
- Investigational peptides
Some articles may also discuss approved medicines or compounds currently being investigated as potential medicines.
The existence of scientific literature about a compound does not mean a Celtek research product is approved for the same purpose.
For example, a published clinical trial may evaluate a pharmaceutical manufacturer’s investigational formulation under a regulated clinical protocol.
A research chemical sold separately by another supplier should not automatically be assumed to be:
- The same formulation
- Manufactured to the same standards
- Clinically equivalent
- Authorized for the same use
Celtek’s research articles are intended to explain scientific evidence rather than establish a therapeutic use for products sold on the site.
Investigational Compounds Require Extra Care
Some peptides discussed in the Celtek research library remain under clinical development.
Retatrutide is an important example.
As of September 2026, retatrutide remains investigational and has not been approved by FDA for any medical indication.
FDA currently states that retatrutide cannot be used in compounding under federal law. FDA also states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
Accordingly, research discussion of retatrutide should not be interpreted as authorization for medical use or pharmaceutical compounding.
Celtek Is Not a Pharmacy
Celtek Peptides is a research chemical and peptide supplier.
Celtek Peptides is not operating as a retail pharmacy dispensing prescription drugs to individual patients.
Celtek research products are not offered as compounded prescription medications.
This distinction matters because pharmaceutical compounding is governed by a separate legal and regulatory framework.
Section 503A
Section 503A of the Federal Food, Drug, and Cosmetic Act provides exemptions from certain drug requirements when specific conditions are satisfied by qualifying compounding pharmacies and physicians.
Among other requirements, FDA explains that 503A compounding generally involves medication compounded for an identified individual patient based on a valid prescription.
Section 503B
Section 503B establishes a framework for registered outsourcing facilities that compound sterile drugs under specific federal requirements.
A research chemical supplier should not be confused with either of these types of pharmaceutical operations.
A Chemical Supplier Is Not a 503A Pharmacy or 503B Outsourcing Facility
Unless Celtek’s legal structure or registrations change, I would make this statement clear on the site:
Celtek Peptides is a research chemical supplier and is not a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Celtek Peptides is not a registered outsourcing facility operating under Section 503B.
I would have counsel verify that exact language against the current corporate setup before publication.
What Pharmaceutical Compounding Means
Compounding involves preparing a drug product to meet a particular medical need under an applicable compounding framework.
FDA notes that compounded drugs are not FDA approved, meaning FDA does not review them for safety, effectiveness, and quality before they are marketed in the same manner as approved drugs.
Federal law also restricts which bulk drug substances qualifying compounders may use.
For 503A compounding, FDA explains that bulk substances generally must meet one of the applicable statutory pathways, such as having an applicable USP/NF monograph, being a component of an FDA-approved drug, or appearing on the appropriate FDA bulk-drug list.
Calling something a “research peptide” does not create a separate pharmaceutical-compounding pathway.
Retatrutide Is a Useful Example
There has been significant online confusion surrounding products marketed as “compounded retatrutide.”
FDA’s current position is unusually direct:
Retatrutide cannot be used in compounding under federal law.
That means terms such as:
- Compounded retatrutide
- Pharmacy-grade retatrutide
- Prescription retatrutide
should not be used casually to describe an RUO research product.
A research material and a legally compounded prescription medication are not interchangeable categories.
Purchaser Responsibilities
Purchasers are responsible for ensuring that research materials are:
- Used only for lawful research purposes
- Handled by appropriately trained personnel
- Stored appropriately
- Used in suitable research facilities
- Disposed of according to applicable requirements
- Used in compliance with federal, state, and local law
Purchasers should also review any applicable institutional requirements, laboratory procedures, safety documentation, and research protocols before working with a compound.
Institutional and Laboratory Use
Research organizations may have additional internal requirements for:
- Chemical inventory
- Material safety
- Institutional review
- Biological research
- Controlled access
- Waste disposal
- Recordkeeping
Celtek’s product documentation does not replace those institutional procedures.
Researchers are responsible for determining what approvals or procedures apply within their own institution.
Product Information Is Not Medical Advice
Nothing on Celtek Peptides should be interpreted as medical advice.
The Celtek research library is designed to explain scientific concepts and published evidence.
References to:
- Weight change
- Blood glucose
- Receptor activity
- Liver fat
- Cardiovascular markers
- Pharmacokinetics
- Clinical-trial adverse events
may be scientifically appropriate when describing a peer-reviewed study.
Those discussions do not mean that Celtek recommends a research product for treating those conditions.
Published Research vs. Product Claims
This distinction should be maintained throughout the site.
Consider these two statements:
Scientific reporting:
In a randomized clinical trial conducted by the drug’s developer, investigators reported an average change in body weight of X%.
That describes published research.
Compare it with:
Product claim:
This peptide causes weight loss.
The second statement may imply an intended therapeutic or structure/function use for the product itself.
FDA’s recent enforcement against peptide sellers shows why this distinction is important. Companies have received warning letters even when their products carried RUO disclaimers because other statements on their websites indicated that the products were intended for human drug use.
Celtek’s educational content should therefore distinguish the published research on a molecule from claims about the research material being sold.
Product Packaging and Labeling
Research-use-only products should be clearly labeled to reflect their intended purpose.
A Celtek research product label may include information such as:
- Compound name
- Product quantity
- Lot number
- Storage information
- Research-use designation
The associated Certificate of Analysis may provide additional analytical information.
Labels should not be interpreted as pharmaceutical prescribing information.
Certificates of Analysis
A Certificate of Analysis documents analytical characteristics of a particular lot.
It may include:
- HPLC purity
- Mass spectrometry
- Molecular weight information
- Lot identification
- Testing date
A COA does not constitute:
- FDA approval
- A prescription
- Clinical certification
- Evidence of human safety
- Authorization for administration
Researchers can locate available reports through the Testing & Certificates of Analysis section.
Questions About Product Status
If you are unsure whether a Celtek product is appropriate for your intended laboratory application, contact Celtek before ordering.
Celtek can answer questions concerning:
- Product identity
- Analytical documentation
- Lot information
- Custom peptide synthesis
- Laboratory specifications
- Storage information
Celtek cannot provide individualized medical advice or instructions for using research products in humans or animals.
Research Use Only Statement
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.
Celtek research products are intended solely for legitimate laboratory research and development unless expressly stated otherwise.
They are not offered for diagnosis, prevention, mitigation, treatment, or cure of disease and are not intended to affect the structure or function of the human or animal body through administration.
Researchers and purchasers are responsible for complying with all laws and institutional requirements applicable to their activities.
References and Regulatory Resources
U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Includes FDA’s current statement that retatrutide cannot be used in compounding under federal law.
FDA guidance on unapproved GLP-1 drugs
U.S. Food and Drug Administration. Gram Peptides Warning Letter, March 31, 2026. Discusses how RUO labeling does not override evidence that a product is intended for human drug use.
FDA Gram Peptides warning letter
U.S. Food and Drug Administration. Wholesale Peptide Warning Letter, June 17, 2026. Another recent example of FDA evaluating overall intended use rather than relying solely on RUO labeling.
FDA Wholesale Peptide warning letter
U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
FDA 503A bulk drug substances guidance
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
FDA compounding questions and answers